Cargando…

Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women

Using a highly sensitive chemiluminescent enzyme immunoassay, we have evaluated the measurement of serum prostate-specific antigen (PSA) as a potential diagnostic test for differentiation between women with breast cancer and those with benign breast disease. In a controlled study consisting of 284 w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romppanen, J, Keskikuru, R, Kataja, V, Eskelinen, M, Kosma, V-M, Savolainen, K, Uusitupa, M, Mononen, I
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362737/ https://www.ncbi.nlm.nih.gov/pubmed/10188910 http://dx.doi.org/10.1038/sj.bjc.6690252

Ejemplares similares

α-Catenin expression has prognostic value in local and locally advanced prostate cancer
por: Aaltomaa, S, et al.
Publicado: (1999)

Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases.
por: Borchert, G. H., et al.
Publicado: (1997)

Is Serum Prostate-specific Antigen a Diagnostic Marker for Benign and Malignant Breast Tumors in Women?
por: Razavi, Seyed Hasan Emami, et al.
Publicado: (2015)

Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues.
por: Howarth, D. J., et al.
Publicado: (1997)

XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study
por: Metsola, Katja, et al.
Publicado: (2005)

Expression of cyclins A and D and p21((waf1/cip1)) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival
por: Aaltomaa, S, et al.
Publicado: (1999)

p21(WAF1/CIP1)expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival
por: Karjalainen, J M, et al.
Publicado: (1999)

p21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis
por: Ropponen, K M, et al.
Publicado: (1999)

Glutathione-linked enzymes in benign and malignant oesophageal tissue
por: Levy, R D, et al.
Publicado: (1999)

Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
por: Heidtmann, H-H, et al.
Publicado: (1999)

Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
por: Yu, H, et al.
Publicado: (1999)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999)

The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen level
por: Coltman, C A
Publicado: (1999)

Adding free to total prostate-specific antigen levels in trials of prostate cancer screening
por: Wald, N J, et al.
Publicado: (2000)

Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions
por: Han, Liying, et al.
Publicado: (2022)

Clinical features of prostate-specific antigen bounce after (125)I brachytherapy for prostate cancer
por: Kubo, Katsumaro, et al.
Publicado: (2018)

Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate
por: Setälä, L P, et al.
Publicado: (1999)

Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2 α in cutaneous melanoma
por: Karjalainen, J M, et al.
Publicado: (2000)

Prostate-specific antigen in serum of women with breast cancer.
por: Giai, M., et al.
Publicado: (1995)

In vitro modelling of epithelial and stromal interactions in non-malignant and malignant prostates
por: Lang, S H, et al.
Publicado: (2000)

Free to total serum prostate specific antigen ratio in symptomatic men does not help in differentiating benign from malignant disease of the prostate
por: Agnihotri, Shalini, et al.
Publicado: (2014)

Impact of Treatment With Statins on Prostate-Specific Antigen and Prostate Volume in Patients With Benign Prostatic Hyperplasia
por: Lee, Sang Hun, et al.
Publicado: (2013)

Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia
por: Hsiao, Chun-Jen, et al.
Publicado: (2016)

Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia
por: Putra, Ida Bagus O.W., et al.
Publicado: (2016)

Comparing the Immunoexpression of FUT3 and FUT6 between Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia
por: de Albuquerque Vasconcelos, Juliana Lúcia, et al.
Publicado: (2013)

Prostate-Specific Antigen Mass and Free Prostate-Specific Antigen Mass for Predicting the Prostate Volume of Korean Men With Biopsy-Proven Benign Prostatic Hyperplasia
por: Park, Tae Yong, et al.
Publicado: (2013)

Free Prostate-Specific Antigen Provides More Precise Data on Benign Prostate Volume Than Total Prostate-Specific Antigen in Korean Population
por: Choi, Hoon, et al.
Publicado: (2013)

Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.
por: Karjalainen, J. M., et al.
Publicado: (1998)

Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
por: Nath, Chandan Kumar, et al.
Publicado: (2020)

Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia
por: Abotsi, Ebenezer, et al.
Publicado: (2022)

The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines
por: Majumdar, S, et al.
Publicado: (1999)

A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland
por: Mononen, N, et al.
Publicado: (2001)

On Chip Immuno-Affinity Profiling of Cancer- and Benign Hyperplasia-Associated Free Prostate Specific Antigen
por: Kosanovic, Maja M., et al.
Publicado: (2011)

Effect of Obesity on Prostate-Specific Antigen, Prostate Volume, and International Prostate Symptom Score in Patients with Benign Prostatic Hyperplasia
por: Kim, Jong Min, et al.
Publicado: (2011)

Evaluation of Molecular Species of Prostate-Specific Antigen Complexed with Immunoglobulin M in Prostate Cancer and Benign Prostatic Hyperplasia
por: Goč, Sanja, et al.
Publicado: (2013)

Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago
por: Press, David J., et al.
Publicado: (2020)

The expression of ABH and Y blood group antigens in benign and malignant breast tissue: the preservation of the H and Y antigens in malignant epithelium.
por: Vowden, P., et al.
Publicado: (1986)

Immunocytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates.
por: Hurkadli, K. S., et al.
Publicado: (1990)

Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone
por: Xu, Bei, et al.
Publicado: (2021)

Ebp1 expression in benign and malignant prostate
por: Gannon, Philippe O, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_vt8um4jkdp93al4va7n5g12afs